IG1102: A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols (FS Grifols) as an adjunct to hemostasis during Parenchymous Tissue open surgeries.
Principal Investigator: Joseph Buell, MD
- Patients are eligible if they require open liver resection surgery.
IG1101: A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols (FS Grifols) as an adjunct to hemostasis during Peripheral Vascular Surgery.
Principal Investigator: Anil Paramesh, MD
- Patients are eligible if they require peripheral vascular procedures including upper extremity dialysis access and bypass grafting.
Sample Collection Cyclosporine.
Principal Investigator: Anil Paramesh, MD
- Patients are eligible if they have received a kidney or liver transplant and are currently taking Cyclosporine.
E5501-G000-311: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure.
Principal Investigator: Fredric Regenstein, MD
- Patients are eligible if they a platelet count of <50 and require a surgical procedure.
A Multi-center, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy
Principal Investigator: Fredric Regenstein, MD
- Patients are eligible if they have received a liver transplant and successfully completed Hepatitis C treatment.
For More Information on the trials listed above, please contact:
Delainna Bartholomew
504-988-6902
dbartho@tulane.edu
Nicole Lassair
504-988-2882
nlassair@tulane.edu